Scienture Holdings, Inc. announced a securities purchase agreement with certain institutional investors.
The agreement involves the purchase of 3,225,000 shares of common stock at an offering price of $1.20 per share.
The gross proceeds for the offering are expected to be approximately $3.9 million before deducting fees and expenses.
Offering Details
3,225,000 shares of common stock at $1.20 per share.
Gross Proceeds
Expected gross proceeds of $3.9 million.
Closing Date
Offering expected to close on August 15, 2025.
Placement Agent
Maxim Group LLC is the sole placement agent for the offering.
Registration Statement
Offering made pursuant to an effective shelf registration statement on Form S-3, filed with the SEC on August 1, 2025.
- The agreement is a significant step for Scienture Holdings, Inc. in raising capital through institutional investors.
- The registered direct offering indicates the company's strategic approach to funding future operations and developments.
This announcement marks a pivotal moment for Scienture Holdings, Inc. as they secure funding through a securities purchase agreement with institutional investors, paving the way for future growth and expansion in the pharmaceutical industry.